Back to Parkinsons Disease

NCT04071847

NCT04071847
Recruiting Not Applicable 🇦🇺 Australian site

Who may be able to join

Who might be able to join this trial:

  • You are scheduled to have a new brain stimulation device implanted, or have an existing device's battery replaced, using an Abbott deep brain stimulation system, within the next 180 days.
  • You (or a legal representative on your behalf) are willing and able to sign a written consent form before any study activities begin.

Who may not be able to join:

  • You are currently taking part in, or planning to join, another research study that could affect the results of this trial.
  • You have physical health conditions, other medical issues, or social or psychological circumstances that, in the doctor's opinion, might make it difficult for you to fully participate or attend follow-up appointments (confirm with trial site).
  • If the trial site is in the United States, your reason for receiving the brain stimulation device is something other than Parkinson's disease or severe, disabling tremor.
  • If the trial site is in the United States, the planned location in the brain where the device leads will be placed is not in one of three specific target areas used for Parkinson's disease or tremor treatment (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Abbott Medical Devices
Registry
clinicaltrials_gov
Start date
26 November 2019
Est. completion
1 September 2029

Where this trial is recruiting

🇦🇺 Australia 🇫🇮 Finland 🇫🇷 France 🇩🇪 Germany 🇮🇹 Italy 🇪🇸 Spain 🇹🇼 Taiwan 🇬🇧 United Kingdom 🇺🇸 United States

2 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Change from baseline to 6 months in disease-specific motor rating scale. For subjects with Parkinson's disease, MDS-UPDRS Part III.; Change from baseline to1 year in disease-specific motor rating scale. For subjects with Parkinson's disease, MDS-UPDRS Part III.; Change from baseline to 2 years in disease-specific motor rating scale. For subjects with Parkinson's disease, MDS-UPDRS Part III.; Change from baseline to 3 years in disease-specific motor rating scale. For subjects with Parkinson's disease, MDS-UPDRS Part III.; Change from baseline to 4 years in disease-specific motor rating scale. F...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov